YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Glioblastoma
  • Glycoproteins
  • Matrix Metalloproteinase 9
  • Oligodendroglioma

abstract

  • YKL-40 and MMP-9 can be monitored in patients' serum and help confirm the absence of active disease in GBM and YKL-40 in anaplastic glioma patients. YKL-40 can be used as predictor of survival in patients with high-grade glioma. Longitudinal studies with a larger patient population are needed to confirm these findings.

publication date

  • October 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-06-0181

PubMed ID

  • 17020973

Additional Document Info

start page

  • 5698

end page

  • 704

volume

  • 12

number

  • 19